{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:51:50Z","timestamp":1787241110509,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011284","name":"Valeant Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011284","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003185","name":"National Psoriasis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004358","name":"Samsung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004358","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.coph.2018.12.001","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T00:40:24Z","timestamp":1547167224000},"page":"14-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Clinical effectiveness of novel rosacea therapies"],"prefix":"10.1016","volume":"46","author":[{"given":"Brittany","family":"Feaster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4464-4727","authenticated-orcid":false,"given":"Abigail","family":"Cline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2018.12.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1080\/19381980.2017.1361574","article-title":"Rosacea: epidemiology, pathogenesis, and treatment","volume":"9","author":"Rainer","year":"2017","journal-title":"DermatoEndocrinology"},{"key":"10.1016\/j.coph.2018.12.001_bib0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000446215","article-title":"Rosacea management","volume":"2","author":"Abokwidir","year":"2016","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.coph.2018.12.001_bib0015","first-page":"17","article-title":"Rosacea management: update on general measures and topical treatments","volume":"6","author":"Schaller","year":"2016","journal-title":"J German Soc Dermatol"},{"key":"10.1016\/j.coph.2018.12.001_bib0020","first-page":"29","article-title":"State of the art: systemic rosacea management","volume":"6","author":"Schaller","year":"2016","journal-title":"J German Soc Dermatol"},{"key":"10.1016\/j.coph.2018.12.001_bib0025","series-title":"(oxymetazoline HCl) Cream 1%","author":"RHOFADE","year":"2017"},{"key":"10.1016\/j.coph.2018.12.001_bib0030","first-page":"28","article-title":"Topical a-agonist therapy for persistent facial erythema of rosacea and the addition of oxymetazoline to the treatment aramentarium: where are we now?","volume":"10","author":"Del Rosso","year":"2017","journal-title":"J Clin Aesthetic Dermatol"},{"key":"10.1016\/j.coph.2018.12.001_bib0035","first-page":"213","article-title":"Clinical pharmacokinetics of oxymetazoline cream following topical facial administration for the treatment of erythema associated with rosacea","volume":"17","author":"Kuang","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.coph.2018.12.001_bib0040","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1060028017740139","article-title":"Role of topical oxymetazoline for management of erythematotelangiectatic rosacea","volume":"52","author":"Hoover","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.coph.2018.12.001_sbref0045","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jaad.2018.01.027","article-title":"Efficacy and safety of oxymetazoline","volume":"78","author":"Draelos","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2018.12.001_bib0050","first-page":"621","article-title":"Clinically relevant reduction in persistent facial erythema of rosacea on the first day of treatment with oxymetazoline cream 1.0%","volume":"17","author":"Tanghetti","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.coph.2018.12.001_bib0055","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1186\/s40064-016-2819-8","article-title":"The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis","volume":"5","author":"Siddiqui","year":"2016","journal-title":"Springerplus"},{"key":"10.1016\/j.coph.2018.12.001_bib0060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/CCID.S98091","article-title":"New developments in the treatment of rosacea- role of once-daily ivermectin cream","volume":"9","author":"Cardwell","year":"2016","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.coph.2018.12.001_bib0065","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1111\/jdv.14437","article-title":"Dual anti inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea","volume":"31","author":"Schaller","year":"2017","journal-title":"Euro Acad Dermatol Venereol"},{"key":"10.1016\/j.coph.2018.12.001_bib0070","first-page":"39","article-title":"Topical ivermectin: data supporting dual modes of action in rosacea","volume":"10","author":"Del Rosso","year":"2017","journal-title":"J Clin Aesthetic Dermatol"},{"key":"10.1016\/j.coph.2018.12.001_bib0075","doi-asserted-by":"crossref","DOI":"10.1007\/s13555-018-0249-y","article-title":"topical ivermectin in the treatment of papulopustular rosacea: a systematic review of evidence and clinical guideline recommendations","author":"Ebbelaar","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.coph.2018.12.001_bib0080","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.clindermatol.2016.10.014","article-title":"Demodex and rosacea revisited","volume":"35","author":"Moran","year":"2017","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.coph.2018.12.001_sbref0085","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s13555-016-0133-6","article-title":"Superior efficacy with ivermectin 1% cream compared to metronidazole 0.75% cream contributes to a better quality of life in patients with severe papulopustular rosacea: a subanalysis of the randomized, investigator-blinded ATTRACT study","volume":"6","author":"Schaller","year":"2016","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.coph.2018.12.001_bib0090","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/jdv.13537","article-title":"Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study","volume":"30","author":"Taieb","year":"2016","journal-title":"Euro Acad Dermatol Venereol"},{"key":"10.1016\/j.coph.2018.12.001_bib0095","first-page":"33","article-title":"Optimizing the use of topical brimonidine in rosacea management: panel recommendations","volume":"14","author":"Tanghetti","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.coph.2018.12.001_bib0100","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2147\/CCID.S58920","article-title":"The role of brimonidine tartrate gel in the treatment of rosacea","volume":"8","author":"Jackson","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.coph.2018.12.001_bib0105","first-page":"909","article-title":"Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: a randomized, vehicle-controlled study","volume":"16","author":"Gold","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.coph.2018.12.001_bib0110","first-page":"16","article-title":"Treatment outcomes of long pulsed Nd: YAG laser for two different subtypes of rosacea","volume":"8","year":"2015","journal-title":"J Clin Aesthetic Dermatol"},{"key":"10.1016\/j.coph.2018.12.001_bib0115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/lsm.20621","article-title":"Rosacea treatment using the new-generation, high energy, 595\u2009nm, long pulse-duration pulsed-dye laser","volume":"40","author":"Bernstein","year":"2008","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.coph.2018.12.001_bib0120","first-page":"38","article-title":"Physical modalities for the treatment of rosacea","volume":"6","author":"Hofmann","year":"2016","journal-title":"J German Soc Dermatol"},{"key":"10.1016\/j.coph.2018.12.001_bib0125","doi-asserted-by":"crossref","first-page":"607","DOI":"10.5021\/ad.2016.28.5.607","article-title":"Prospective comparison of dual wavelength long-pulsed 755-nm alexandrite\/1064-nm neodymium:yttrium-aluminum-garnet laser versus 585-nm pulsed dye laser treatment for rosacea","volume":"28","author":"Seo","year":"2016","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.coph.2018.12.001_bib0130","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/DSS.0000000000000968","article-title":"Comparative efficacy of radiofrequency and pulsed dye laser in the treatment of rosacea","volume":"43","author":"Kim","year":"2017","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.coph.2018.12.001_bib0135","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.cps.2016.03.015","article-title":"Minimally invasive radiofrequency devices","volume":"43","author":"Sadick","year":"2016","journal-title":"Clin Plastic Surg"},{"key":"10.1016\/j.coph.2018.12.001_sbref0140","first-page":"1298","article-title":"Expanding the clinical application of fractional radiofrequency treatment: findings on rhytides, hyperpigmentation, rosacea, and acne redness","volume":"14","author":"Hongcharu","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.coph.2018.12.001_bib0145","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1097\/DSS.0000000000000888","article-title":"Clinical and histologic effects of fractional microneedling radiofrequency treatment on rosacea","volume":"42","author":"Park","year":"2016","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.coph.2018.12.001_bib0150","first-page":"1","article-title":"Dual-frequency ultrasound as a new treatment modality for refractory rosacea: a retrospective study","volume":"0","author":"Park","year":"2018","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.coph.2018.12.001_bib0155","doi-asserted-by":"crossref","first-page":"543","DOI":"10.5021\/ad.2017.29.5.543","article-title":"Pulsed dye laser treatment combined with oral minocycline reduces recurrence rate of rosacea","volume":"29","author":"Soo Ko","year":"2017","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.coph.2018.12.001_bib0160","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s10103-017-2318-3","article-title":"Treatment of erythemato-telangiectatic rosacea with brimonidine alone or combined with vascular laser based on preliminary instrumental evaluation of the vascular component","volume":"33","author":"Micali","year":"2017","journal-title":"Lasers Med Sci"},{"key":"10.1016\/j.coph.2018.12.001_bib0165","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bjd.15173","article-title":"Rosacea treatment update: recommendations from the global ROSacea Consensus (ROSCO) panel","volume":"176","author":"Schaller","year":"2017","journal-title":"Br J Dermatol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218301103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218301103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:51:10Z","timestamp":1761461470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489218301103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":33,"alternative-id":["S1471489218301103"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2018.12.001","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical effectiveness of novel rosacea therapies","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2018.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}